Leading Resource on Biosimilars
Biosimilars Council (biosimilarscouncil.org) scores 75 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, Non-profit brands, Government brands, in the 42nd percentile of 11562 Healthcare brands.
The Biosimilars Council is a division of the Association for Accessible Medicines that advocates for biosimilar medicines in the United States. It provides data, policy insights, and advocacy aimed at supporting biosimilar adoption, improving patient access, and lowering healthcare costs while maintaining patient safety. Its primary audience includes policymakers, regulators, healthcare professionals, and industry stakeholders in the generic and biosimilar medicines sector.
| Brand Name | Biosimilars Council |
|---|---|
| Domain | biosimilarscouncil.org |
| Industry | Healthcare, Non-profit |
| Parent Company / Owner | Association for Accessible Medicines |
| Main Competitors | Biotechnology Innovation Organization (85/100), PhRMA (83/100), Alliance for Safe Biologic Medicines |
Moz Domain Authority 37/100 vs category average 41 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
Ranked #4,294,696 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "The Biosimilars Council, a division of the Association for Accessible Medicines, works to ensure a positive future for biosimilar medicines." (Meta description: 20 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Breadcrumb/Website schema, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, WordPress, Ghost.
Social footprint: verified profiles on LinkedIn, X (Twitter), Facebook, YouTube, Instagram; no detected presence on GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Biosimilars Council?", Claude could identify the brand as of October 2026. The Biosimilars Council is a division of the Association for Accessible Medicines (AAM) that advocates for the development, approval, and use of biosimilar medicines in the United States. Best known for Advocacy and policy work promoting biosimilar drug adoption and education in the US healthcare market.
When asked "Best brands similar to Biosimilars Council?", Claude would recommend Biosimilars Council as of October 2026. It's a recognized industry group in the biosimilars policy space, so it would come up naturally if someone asked about organizations advocating for biosimilar medicines.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Biosimilars Council's main competitors in Healthcare: Biotechnology Innovation Organization (85/100), PhRMA (83/100).
Sources: Brand Analyzer scan
The Biosimilars Council is a division of the Association for Accessible Medicines dedicated to ensuring a positive future for biosimilar medicines in the United States. It functions as an advocacy and policy organization within the healthcare and non-profit sector.
Sources: Biosimilars Council official site
Biosimilars Council has low AI-search visibility, scoring 18/100 on Brand Analyzer's AI visibility composite (visibility 0, trust 23, recommendation 45). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Biosimilars Council official site
The Biosimilars Council works to support biosimilar adoption and access in the U.S. by providing authoritative data, policy insights, and advocacy. It engages with policymakers and regulators to promote policies that enable a sustainable market for biosimilar medicines while maintaining patient safety and helping lower healthcare costs.
Sources: Biosimilars Council official site
The Biosimilars Council offers policy advocacy, authoritative data, and policy insights related to biosimilar medicines. Its work is aimed at supporting biosimilar adoption and access, helping lower healthcare costs while maintaining patient safety for the U.S. market.
Sources: Biosimilars Council official site
Biosimilars Council scores 45/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Biosimilars Council official site
Biosimilars Council can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Biosimilars Council official site
The Biosimilars Council's work is used by policymakers, regulators, healthcare professionals, and industry stakeholders involved in the U.S. generic and biosimilar medicines sector.
Sources: Biosimilars Council official site
The Biosimilars Council is known for being a leading authority and advocate for biosimilar medicines in the U.S., operating as a division of the Association for Accessible Medicines and focusing on policy advocacy related to biosimilar access and adoption.
Sources: Biosimilars Council official site
Biosimilars Council scores 18/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Biosimilars Council has a weak AI-visibility profile at 18/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (45/100) and its weakest is visibility (0/100). It benefits from a global traffic rank of #4,294,696 (Tranco) and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, no strong Wikidata entry and a low Moz Domain Authority of 37/100. In a live check, Claude could already identify Biosimilars Council from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Biosimilars Council: BioRender (75/100), Bionaire (75/100), Biotta (75/100), Bloomberg Philanthropies (75/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.